新城發展(01030.HK):擬通過配售股份籌資27.3億港元
格隆匯1月14日丨新城發展(01030.HK)公佈,於2019年1月14日,公司擬向不少於6名投資者配售最多3.11億股,佔經擴大後公司股份5.01%。配售價為每股8.78港元,較昨日收市價每股9.05港元折讓約2.98%。預期所得款項總額將約為27.31億港元及所得款項淨額約為27.11億港元。
公告稱,進行配售事項旨在補充集團長期擴張及成長計劃的所需資金。董事認為,配售事項將為公司提供一個籌集更多資金的機會,同時拓寬其股東基礎,優化其資本結構,併為集團提供資金以滿足未來可能的發展。假設全部配售股份均已根據配售協議獲悉數配售,公司擬將所有配售事項估計所得款項淨額用公司長遠的業務發展,以及作為集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.